TruNorth Capital Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$859K Buy
742
+114
+18% +$135K 0.13% 52
2026
Q2
$753K Buy
628
+3
+0.5% +$3.06K 0.12% 56
2026
Q1
$575K Hold
625
– – 0.11% 56
2025
Q4
$672K Buy
625
+237
+61% +$227K 0.13% 55
2025
Q3
$296K Buy
388
+56
+17% +$41.7K 0.06% 74
2025
Q2
$259K Sell
332
-3
-0.9% -$2.33K 0.06% 75
2025
Q1
$277K Hold
335
– – 0.07% 80
2024
Q4
$259K Hold
335
– – 0.07% 60
2024
Q3
$297K Buy
335
+11
+3% +$9.89K 0.09% 54
2024
Q2
$293K Sell
324
-16
-5% -$12.8K 0.1% 53
2024
Q1
$265K Buy
+340
New +$242K 0.09% 50

Other funds holding LLY

TruNorth Capital Management's LLY Position: Q3 2026 in Review

TruNorth Capital Management increased its Eli Lilly (LLY) stake by 18% in Q3 2026, buying an estimated $135K and bringing the position to 742 shares worth $859K. The position accounts for 0.13% of the portfolio, ranked #52.

TruNorth Capital Management first reported a position in LLY in Q1 2024 and has held it in 11 quarters since. 565 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • TruNorth Capital Management held 742 shares of Eli Lilly worth $859K as of Q3 2026.
  • TruNorth Capital Management bought 114 Eli Lilly shares in Q3 2026, an estimated $135K.
  • Eli Lilly made up 0.13% of TruNorth Capital Management's portfolio in Q3 2026, its #52 holding.
  • TruNorth Capital Management first reported a position in Eli Lilly in Q1 2024 and has held it in 11 quarters since.
  • 565 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on TruNorth Capital Management's 13F filing for Q3 2026, filed 14 Oct 2026.